Ligand Pharmaceuticals Inc (LGND)
70.23
-0.23
(-0.33%)
USD |
NASDAQ |
Apr 30, 14:41
Ligand Pharmaceuticals Price to Book Value: 1.774 for April 30, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| April 29, 2024 | 1.780 |
| April 26, 2024 | 1.783 |
| April 25, 2024 | 1.778 |
| April 24, 2024 | 1.794 |
| April 23, 2024 | 1.765 |
| April 22, 2024 | 1.731 |
| April 19, 2024 | 1.831 |
| April 18, 2024 | 1.832 |
| April 17, 2024 | 1.992 |
| April 16, 2024 | 2.019 |
| April 15, 2024 | 2.015 |
| April 12, 2024 | 2.055 |
| April 11, 2024 | 2.057 |
| April 10, 2024 | 2.040 |
| April 09, 2024 | 2.059 |
| April 08, 2024 | 2.011 |
| April 05, 2024 | 1.969 |
| April 04, 2024 | 1.970 |
| April 03, 2024 | 1.888 |
| April 02, 2024 | 1.849 |
| April 01, 2024 | 1.859 |
| March 28, 2024 | 1.846 |
| March 27, 2024 | 1.800 |
| March 26, 2024 | 1.734 |
| March 25, 2024 | 1.749 |
| Date | Value |
|---|---|
| March 22, 2024 | 1.794 |
| March 21, 2024 | 1.843 |
| March 20, 2024 | 1.847 |
| March 19, 2024 | 1.824 |
| March 18, 2024 | 1.822 |
| March 15, 2024 | 1.796 |
| March 14, 2024 | 1.817 |
| March 13, 2024 | 1.838 |
| March 12, 2024 | 1.828 |
| March 11, 2024 | 1.825 |
| March 08, 2024 | 1.864 |
| March 07, 2024 | 1.831 |
| March 06, 2024 | 1.837 |
| March 05, 2024 | 1.869 |
| March 04, 2024 | 1.927 |
| March 01, 2024 | 1.988 |
| February 29, 2024 | 2.004 |
| February 28, 2024 | 2.131 |
| February 27, 2024 | 2.253 |
| February 26, 2024 | 1.880 |
| February 23, 2024 | 1.900 |
| February 22, 2024 | 1.842 |
| February 21, 2024 | 1.820 |
| February 20, 2024 | 1.813 |
| February 16, 2024 | 1.845 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
1.283
Minimum
Nov 04 2022
4.891
Maximum
Feb 09 2021
2.216
Average
2.072
Median
Price to Book Value Benchmarks
| ANI Pharmaceuticals Inc | 3.235 |
| ADMA Biologics Inc | 11.22 |
| Viking Therapeutics Inc | 9.392 |
| Corcept Therapeutics Inc | 4.802 |
| Palatin Technologies Inc | -- |
Price to Book Value Related Metrics
| PE Ratio | 24.22 |
| PS Ratio | 9.461 |
| Price | 70.23 |
| Earnings Yield | 4.13% |
| Market Cap | 1.243B |
| Operating PE Ratio | 126.50 |
| Normalized PE Ratio | 76.17 |